Board of Directors approved the financial reports for the second quarter of 2022
· Issued by Maxigen Biotech Inc.
Close
Today's Information
Provided by: MAXIGEN BIOTECH INC.
SEQ_NO
1
Date of announcement
2022/08/03
Time of announcement
20:48:37
Subject
Board of Directors approved the financial reports
for the second quarter of 2022
Date of events
2022/08/03
To which item it meets
paragraph 31
Statement
1.Date of submission to the board of directors or approval by the board of
directors:2022/08/03
2.Date of approval by the audit committee:2022/08/03
3.Start and end dates of financial reports or annual self-assessed financial
information of the reporting period (XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):277487
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):156398
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):39715
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):59331
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):54032
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):54032
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.70
11.Total assets end of the period (thousand NTD):1316744
12.Total liabilities end of the period
(thousand NTD):113756
13.Equity attributable to owners of parent end of the
period (thousand NTD):1202988
14.Any other matters that need to be specified:None
